Back to all companies
Sign in
Back to all companies
Enzyme logo

Enzyme

Summer 2017Acquired

Automating regulatory approval & compliance for life science companies

Save
Enzyme logo

Enzyme

Summer 2017Acquired

Automating regulatory approval & compliance for life science companies

Save
Company details

Enzyme provides online quality management system software and supportive QA/RA consulting, helping life science companies with FDA approval and ongoing compliance. Enzyme staff has over 50 years of medical device industry experience, across several Fortune 500 companies and startups.

Location
San Francisco, CA, USA; Remote
Founded
2017
Category
SaaS
YC Directory Pagewww.enzyme.com
Founders
  • JS
    Jared Seehafer
    Founder/CEO
    X / TwitterLinkedIn
  • JG
    Jacob Graham
    Founder/Vice President QA/RA
    LinkedIn

Enzyme provides online quality management system software and supportive QA/RA consulting, helping life science companies with FDA approval and ongoing compliance. Enzyme staff has over 50 years of medical device industry experience, across several Fortune 500 companies and startups.

Location
San Francisco, CA, USA; Remote
Founded
2017
Category
SaaS
YC Directory Pagewww.enzyme.com
Founders
  • JS
    Jared Seehafer
    Founder/CEO
    X / TwitterLinkedIn
  • JG
    Jacob Graham
    Founder/Vice President QA/RA
    LinkedIn

Pressure-test this opportunity

Turn this teardown into a decision-ready prompt for ChatGPT, Claude, or your agent.

On this page
  • Overview
  • Founding Story
  • Timeline
  • What They Built
  • Market Position
  • Target Customers
  • Market Size
  • Competition
  • Business Model
  • Traction
  • Post-Mortem
  • Product trust created a scale obligation
  • Capital changed ownership before it changed distribution
  • The product survived because it fit a consolidator
  • Key Lessons
  • Sources

This report was generated by our Deep Research agent and may contain mistakes.

Did we get something wrong? DM @oscrhong and we'll fix it ASAP!

Startups.RIP — Dead startups, alive ideas
PricingContactPrivacyGot feedback? DM @oscrhong
Exec Briefing

Actionable insights

If you only have a few minutes to spare, here’s what investors, operators, and founders should know about Enzyme (S17).

  1. Integration opened the door. Connecting engineering tools to compliance records solved an immediate duplication problem, but customers eventually expected a complete quality platform.
  2. Expertise sold trust. The founders had performed submissions, design assurance, and quality work themselves. That credibility mattered when buyers were putting regulator-facing records into a startup's software.
  3. Services carried two costs. Consulting helped small teams adopt the product, while tying growth to scarce regulatory talent and a larger support obligation.
  4. Distribution outgrew ownership. A strategic majority shareholder supplied capital in 2022. The final buyer supplied a 1,100-company base, broader lifecycle software, and the operating infrastructure customers needed.

Overview

Enzyme built an electronic quality-management system for life-science companies from 2017 until Greenlight Guru acquired it in July 2025. [7] The product joined document control, training, design controls, risk, audits, complaints, nonconformance, CAPA, and regulatory consulting in one system. Its first wedge was unusually concrete: connect the engineering tools a startup already used and turn the work into inspection-ready evidence. [1] [6]

Enzyme proved that small medical-device teams would buy a friendlier QMS, attracted a public-company majority shareholder, and survived into a strategic acquisition. [3] The constraint appeared after validation: regulated software creates an expanding obligation to maintain infrastructure, support, validation, and domain expertise. In that market, the installed base and operating capacity of a broader platform eventually mattered more than an independent product's elegance.

Portrait of Enzyme co-founder Jacob Graham
Jacob Graham brought more than a decade of medical-device quality work to Enzyme's product design.
Portrait of Enzyme co-founder Jared Seehafer
Jared Seehafer turned firsthand submission and device-development work into Enzyme's founding premise.

Image 1 / 2

Founding Story

Jared Seehafer and Jacob Graham had spent years doing the work Enzyme would later encode. Seehafer's background included product and regulatory roles at St. Jude Neuromodulation and Medtronic Diabetes. He held an MS in Medical Device Engineering from USC and a Regulatory Affairs Certification. [5] Graham spent more than a decade in medical-device engineering, design assurance, and quality systems at Boston Scientific, Medtronic, and a startup. [3]

Their complaints came from opposite sides of the same process. Seehafer had co-founded a consulting firm that helped companies prepare submissions. Graham had watched quality work fragment across disconnected enterprise systems. The company's public handbook described delays of weeks or months when people lacked access to one of those systems or used it too infrequently to work efficiently. [4]

In 2016, Seehafer approached his friend with the idea for one cloud application. Graham recalled: "I would routinely log into 4–6 different technology platforms for training, performance, compliance, and more, and I knew there had to be a more streamlined way." He said their backgrounds fit because his workflow knowledge complemented Seehafer's medical-device and software experience. [3]

Seehafer put the founding insight more bluntly in a 2018 TechCrunch interview: "You find you spend almost as much time documenting the work as you do doing the work." He followed it with the question that became the product thesis: "This is a multitrillion-dollar industry and I thought 'why isn't there software to automate the process?'" [2]

Enzyme launched in 2017 and joined YC's Summer batch. Refactor Capital said the founders' direct knowledge of the regulatory maze was central to its investment thesis. [10]

Timeline

  • 2016: Seehafer brought Graham the idea for a unified, cloud-hosted quality system. [3]
  • Summer 2017: Enzyme launched out of beta, integrated with Jira, Trello, and GitHub, and joined YC S17. [1] [2]
  • January 2018: The company reported $1.85 million raised and about 10 customers. [2]
  • 2022: Roivant Sciences became the majority shareholder; Enzyme remained independently operated. [3]
  • July 2025: Seehafer left as CEO and Greenlight Guru acquired Enzyme; the announcement did not disclose a price. [7]

What They Built

Enzyme started with a useful distinction: engineering teams already produced much of the evidence regulators needed, but the evidence lived in tools built for shipping software rather than defending a quality system. Its early product connected Jira, Trello, and GitHub so a startup did not need to copy the same work into a separate compliance system. [2]

The product expanded into a modular eQMS. Its core covered controlled documents, training, electronic signatures, and integrations. Premarket work added design controls, risk management, and supplier records. Postmarket work covered audits, complaints, nonconformance, and corrective and preventive actions. Enzyme also listed an electronic trial master file module. Customers chose Core, Premarket, or Postmarket packages and paid according to both plan and user type; Lite users could view materials and sign off on training, while Full users operated the system. [6]

Unlock the full Enzyme teardown

Read the complete post-mortem, the rebuild playbook, and the exact reasons Enzyme is still worth studying now.

See Pro plans